Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 16S ribosomal RNA (16S rRNA) is the primary RNA component of the small (30S) subunit of the prokaryotic ribosome. It plays a fundamental role in protein synthesis by acting as a structural scaffold for ribosomal proteins and, crucially, by facilitating the decoding of messenger RNA (mRNA) through codon-anticodon pairing at the aminoacyl-tRNA site (A-site). Because of its essential role in bacterial translation, 16S rRNA is a major therapeutic target for several classes of clinically vital antibiotics, including aminoglycosides and tetracyclines. Aminoglycosides bind to the decoding center of the 16S rRNA, inducing conformational changes that cause mRNA misreading and mistranslation, whereas tetracyclines physically block the entry of aminoacyl-tRNA into the A-site. Due to structural differences between prokaryotic 16S rRNA and eukaryotic 18S rRNA, these drugs exhibit high selectivity for bacterial cells. However, off-target binding to human mitochondrial 12S rRNA, which shares structural homology with 16S rRNA, can lead to severe adverse effects such as ototoxicity. Additionally, mutations in the 16S rRNA gene or enzymatic methylation of specific nucleotides by bacterial methyltransferases represent major mechanisms of antibiotic resistance, making the sequence of 16S rRNA a critical biomarker for pathogen identification and resistance profiling.
Aminoglycosides bind to the decoding A-site (specifically helix 44) of the 16S rRNA, inducing conformational changes in key nucleotides (such as A1492 and A1493) that decrease translational accuracy, cause mRNA misreading, and inhibit translocation. Tetracyclines bind to the 16S rRNA near the A-site (specifically helix 31), physically blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex and thereby halting translation elongation. Spectinomycin binds to the 16S rRNA to block translocation by preventing elongation factor G attachment.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 16S ribosomal RNA (16S rRNA) (16S rRNA).